Resources

Filter

Filter by:

infographic

Understanding the Stakes of IND Submissions: Why Timely Approvals Matter

post

291 FDA Complete Response Letters Decoded: Insights for Biologics CMC Strategy

post

Oral Drug Product Development of Small Molecules

webinar

Ask Me Anything Series – CMC and Regulatory Alignment: Lessons from the Front Lines

post

Quality tools: Resources for Quality Control Specialists in Medical Writing

white-paper

The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China

post

Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in

post

From Fast Track to PreCheck: A New Era in FDA Readiness Programs

white-paper

Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?

white-paper

BioPharma Due Diligence in a Shifting Global Market

post

The Startup’s Guide: 10 Must-Have CMC SOPs for Virtual Pharma in Phase 1

white-paper

The CMC Trap: How Chemistry, Manufacturing, and Controls Failures Derail Drug Development

post

FDA PreCheck Pilot: A Smarter, Infrastructure-Centered Alternative to Fast Track and Breakthrough Designations

infographic

The Business Case for Investing in CMC: Protecting Your Asset and Ensuring Success

post

Why Strong Technical + Regulatory Alignment Matters

post

Managing Complexity: How Strategic Execution Drove a Cleanroom Upgrade Project to Completion

post

Building a QMS (Quality Management System) for Medical Device

white-paper

Future Challenges in Biopharmaceutical Workforce Development

case-study

Driving Long-Term Value Through a People-Centered, Execution-Focused Approach to M&A Integration

infographic

Minimize Disruption, Maximize Efficiency

post

Manufacturing Gaps in the U.S. Pharmaceutical Industry Exposed by Tariff Wars

white-paper

Assessing Animal-Derived Raw Materials for Viral Risk

post

The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains

post

Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group